SCHEMBL2819745

SCHEMBL2819745

Cc1ccc(Oc2ccc([N+](=O)[O-])cc2S(=O)(=O)N2CCNCC2)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 2/20 0.51
LMNA P02545 2/20 0.51
TBXA2R P21731 3/20 0.47
ALDH1A1 P00352 7/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HPGD P15428 1/20 0.46
MCOLN3 Q8TDD5 1/20 0.46
MAPT P10636 1/20 0.46
HTR6 P50406 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2C9 P11712 1/20 0.42
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818876 0.92 TBXA2R (0.57) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2823427 0.91 L3MBTL1 (0.53) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2818841 0.89 KMT2A (0.53) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2821022 0.89 L3MBTL1 (0.51) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2819893 0.87 L3MBTL1 (0.51) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2823186 0.87 KMT2A (0.62) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2819885 0.87 TBXA2R (0.55) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2821962 0.86 ALDH1A1 (0.53) L3MBTL1KMT2ALMNATBXA2RALDH1A1
Hydrochloric Acid SCHEMBL3014573 0.86 L3MBTL1 (0.50) L3MBTL1KMT2ALMNATBXA2RALDH1A1
SCHEMBL2820559 0.86 KMT2A (0.48) L3MBTL1KMT2ALMNATBXA2RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1849469-B1 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC (US) 2010-10-27 EP claimed
US-7700586-B2 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS, INC. (US) 2010-04-20 US claimed
US-8242118-B2 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC. (US) 2012-08-14 US disclosed
US-20100204213-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS BAYER HEALTHCARE AG (DE) 2010-08-12 US disclosed
US-7700586-B2 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS, INC. (US) 2010-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204213-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS CCR3, CCR1, CCR2 L3MBTL1 4577/4885KMT2A 2753/4885LMNA 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.